CARDHOLDER S NAME SIGNATURE CARD NUMBER EXP. DATE. Nurses/Residents/Students* (*proof of eligibility must accompany registration)...

Transcription

1 REGISTRANT INFORMATION Registration Fees A O Check if you require special facilities or assistance and attach a note with specific details and requirements. Payment Method DEGREE: O MD O PhD O PharmD O RN O Other SPECIALTY: O Hematology O Medical Oncology O Radiation Oncology FIRST NAME MI LAST NAME O Pathology O Surgery O Nursing O Other ADDRESS TELEPHONE FAX INSTITUTE DEPARTMENT ADDRESS CITY STATE/PROVINCE ZIP/POSTAL CODE COUNTRY O American Express O MasterCard O Visa O Check in the amount of $ CARDHOLDER S NAME SIGNATURE CARD NUMBER EXP. DATE 4325 Alexander Drive Alpharetta, GA , USA Great Debates and Updates in April 17-18, 2009 Boca Raton, Florida, USA Important Dates Registration Deadline April 9, 2009 Meeting Dates April 17 18, 2009 Quotes The best educational event that happened all year! Great topics Difficult to improve 3 ways To Learn: PRINT materials are produced by Imedex for your reference needs ONLINE products are produced by Imedex in 6 user-friendly formats LIVE meetings are produced by Imedex in 15 countries Visit to learn more. Regular...O $150 Nurses/Residents/Students* (*proof of eligibility must accompany registration)...o $75 25% Imedex is committed to environmental excellence. This publication is printed on paper, which is acid-free and contains 30% post-consumer waste.

2 Great Debates and Updates in Organized for Organized for April 17-18, 2009 Boca Raton, Florida, USA Chairs James Armitage, MD University of Nebraska Medical Center Omaha, Nebraska Jorge Cortes, MD University of Texas M. D. Anderson Cancer Center Robert Orlowski, MD, PhD University of Texas M. D. Anderson Cancer Center 2nd Announcement W W W. I M E D E X. C O M

3 Great Debates and Updates in April 17-18, 2009 I Boca Raton, Florida, USA Conference Summary Great Debates and Updates in will cover the broad continuum of hematologic malignancies from lymphoma and leukemia to myeloma and myeloproliferative disorders in order to provide the broadest appeal to attendees and to offer a most substantial curriculum. This educational activity will use a combination of didactic presentations and debates on controversial topics in hematology that you will find both enjoyable and educational. Nationally recognized thought leaders will take opposing positions on a topic of interest and provide you with an insightful look at more than one side of a question. Discussions will focus on how the new data fit into the current community practice of hematology, and will be aimed at facilitating rapid incorporation of important new therapeutic advances into your current practice. Conference Organizer 4325 Alexander Drive Alpharetta, Georgia , USA Tel.: +1 (770) Fax: +1(770) meetings@imedex.com Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED. In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual s own physician. Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

4 Great Debates and Updates in April 17-18, 2009 I Boca Raton, Florida, USA continuing medical education Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Imedex, LLC designates this educational activity for a maximum of AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. Who Should Attend This educational activity is specifically designed for academic and community hematologists, oncologists, oncology nurses and any other healthcare professional interested or involved in the management and treatment of patients with hematologic malignancies. Objectives After successful completion of this course, attendees should be able to: Evaluate conservative therapy versus curative intent in patients with nodular lymphocyte predominant Hodgkin s lymphoma Differentiate implications of the microenvironment versus tumor cells in follicular lymphoma Compare and contrast traditional and emerging therapies for patients with non-hodgkin s lymphoma Describe emerging therapies in lymphoproliferative diseases and evaluate the practical utility of these agents based on data from clinical studies Integrate appropriate and/or novel therapies for multiple myeloma into clinical practice based on interpretation of recent clinical trial data Identify and properly manage patients with monoclonal gammopathy of unknown significance who are likely to progress to active multiple myeloma Discuss available front-line therapy options for patients with high-risk newly diagnosed chronic myelogenous leukemia and identify strategies to employ the optimal management strategy based on patient characteristics Summarize available treatment options for patients with myelodysplastic syndromes, focusing on the benefits and limitations of current treatment strategies compared to emerging management therapies Determine the appropriate therapy for patients with newly diagnosed or relapsed chronic lymphocytic leukemia

5 Corporate Support The following companies have provided educational grants in support of this conference: Platinum Millennium Pharmaceuticals, Inc. Silver Gold Genentech BioOncology and Biogen Idec Hotel Accommodations Boca Raton Resort & Club 501 East Camino Real Boca Raton, Florida Tel.: +1 (561) Tel: +1 (888) Fax: +1 (561) Situated on 356 acres in fabled South Florida, Boca Raton Resort & Club carefully combines a fresh look and modern amenities, while embracing the purpose and design of the original vision of renowned architect Addison Mizner. Exquisite accommodations within this captivating Boca Raton hotel are presented within five distinct settings ranging from the ultra-luxe Beach Club to the sleek, contemporary Bungalows. With deep roots in the past, this completely unique Boca Raton Florida hotel is truly a destination for the future. Nestled on 356 breathtaking resort-style acres in Boca Raton, Florida A private village, offering five distinctive settings for accommodations Bronze Bordered by a half-mile of private beach along Florida s Gold Coast in Palm Beach County Just 24 miles north of Fort Lauderdale / Hollywood International Airport (FLL) Corporate Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) , or by at cme@imedex.com. Only 28 miles south from Palm Beach International Airport (PBI) For the convenience of attendees, a limited number of rooms have been reserved until March 18, 2009 at a discounted rate of $ single/double occupancy, plus tax, currently at 11.5%. This rate is not guaranteed outside the conference dates or after March 18, To reserve your room please contact the Boca Raton Resort & Club reservations department at or

6 Faculty Kenneth C. Anderson, MD, MA Dana-Farber Cancer Institute Boston, Massachusetts Stephen M. Ansell, MD, PhD Mayo Clinic College of Medicine Rochester, Minnesota James Armitage, MD University of Nebraska Medical Center Omaha, Nebraska Steven H. Bernstein, MD University of Rochester School of Medicine and Dentistry Rochester, New York Jorge Cortes, MD M.D. Anderson Cancer Center Rafael Fonseca, MD Mayo Clinic College of Medicine Scottsdale, Arizona Steven M. Horwitz, MD Memorial Sloan-Kettering Cancer Center New York, New York Matt Kalaycio, MD Taussig Cancer Center Cleveland, Ohio Michael J. Keating, MB, BS M.D. Anderson Cancer Center John P. Leonard, MD Weill Cornell Medical College New York, New York Brian K. Link, MD The University of Iowa College of Medicine Iowa City, Iowa Sagar Lonial, MD Emory University Atlanta, Georgia Ann F. Mohrbacher, MD University of Southern California Los Angeles, California Craig Moskowitz, MD Memorial Sloan-Kettering Cancer Center New York, New York Nikhil C. Munshi, MD Dana-Farber Cancer Institute Boston, Massachusetts Stephen Nimer, MD Memorial Sloan-Kettering Cancer Center New York, New York Robert Z. Orlowski, MD, PhD M.D. Anderson Cancer Center S. Vincent Rajkumar, MD Mayo Clinic College of Medicine Rochester, Minnesota Gail Roboz, MD Weill Medical College New York, New York Kerry J. Savage, MD, MSc, FRCPC British Columbia Cancer Agency Vancourver, British Columbia, Canada David P. Steensma, MD Mayo Clinic College of Medicine Rochester, Minnesota Julie Vose, MD University of Nebraska Medical Center Omaha, Nebraska William G. Wierda, MD, PhD M.D. Anderson Cancer Center Michael E. Williams, MD University of Virginia School of Medicine Charlottesville, Virginia Michael J. Mauro, MD Oregon Health and Science University Portland, Oregon

7 Great Debates and Updates in April 17-18, 2009 I Boca Raton, Florida, USA scientific agenga friday, april 17, :00 am Breakfast 8:00 am Welcome and introduction James Armitage, MD Chair Jorge Cortes, MD Chair Robert Orlowski, MD, PhD Chair Jim Epstein, MD Moderator Hodgkin s Lymphoma 8:10 am Debate: Nodular lymphocyte predominant Hodgkin s lymphoma Conservative therapy Speaker invited Curative therapy Kerry J. Savage, MD, MSc, FRCPC Non-Hodgkin s Lymphoma 8:40 am Debate: What is the most appropriate second line therapy for a follicular lymphoma patient who received frontline R-CHOP and relapses 4 months after completing maintenance rituximab? Bendamustine based therapy Steven H. Bernstein, MD Radioimmunotherapy Stephen M. Ansell, MD, PhD Stem Cell Transplant Julie Vose, MD 9:15 am Debate: Should the newly recognized biological sub-groups guide our treatment for diffuse large B-Cell Lymphoma? No Brian K. Link, MD Yes Craig Moskowitz, MD 9:45 am Debate: Should all aggressive peripheral T-Cell lymphomas be treated in the same manner? No Julie Vose, MD Yes Steven M. Horwitz, MD 10:15 am Coffee break 10:30 am Debate: Should CLL/SLL sub-groups that have deletion 17p or who have the best prognostic features be treated differently than the average CLL/SLL patient? No William G. Wierda, MD, PhD Yes Michael E. Williams, MD 11:00 am Debate: Is there still a role for Watch & Wait in follicular lymphoma? No Speaker invited Yes John P. Leonard, MD 11:30 am Lunch Lymphoma 12:15 pm Symposium on Emerging Therapies in Lymphoproliferative Diseases: Monoclonal antibodies Brian K. Link, MD Proteasome inhibitors John P. Leonard, MD Syk inhibitors Steven H. Bernstein, MD mtor inhibitors Stephen M. Ansell, MD, PhD Epigenetic targeted agents Steven M. Horwitz, MD BCL-2 inhibitors William G. Wierda, MD, PhD Immunomodulatory agents Craig Moskowitz, MD 2:00 pm Panel for Q & A audience submitted questions 2:30 pm Coffee break

8 Myeloma 2:50 pm Don t get blind-sided by Mr. MGUS How to identify those MGUS patients most likely to progress to active Multiple Myeloma S. Vincent Rajkumar, MD 3:20 pm Debate: Is multiple myeloma curable without resorting to allogeneic SCT? No Sagar Lonial, MD Yes S.Vincent Rajkumar, MD 3:50 pm Debate: Is CR/nCR the Holy Grail for front line therapy of myeloma? No Kenneth C. Anderson, MD Yes Rafael Fonseca, MD 4:20 pm Novel therapies for multiple myeloma 4:45 pm Adjourn Kenneth C. Anderson, MD Saturday, April 18, :00 am Breakfast 8:00 am Welcome and introduction James Armitage, MD Chair Jorge Cortes, MD Chair Robert Z. Orlowski, MD, PhD Chair Jim Epstein, MD Moderator 8:10 am Debate: Are alkylating agents still necessary components of front line therapy for older, transplant ineligible patients? No Robert Z. Orlowski, MD, PhD Yes Nikhil C. Munshi, MD 8:40 am Should Auto-SCT be performed during the first remission or second remission or does it matter? Rafael Fonseca, MD 9:05 am Debate: Is it possible to decide on the basis of available clinical and molecular prognostic factors for multiple myeloma whether a patient should receive front line therapy with an immunomodulatory compound or a proteasome inhibitor or both? No Nikhil C. Munshi, MD Yes Sagar Lonial, MD 9:35 am Debate: Should the International Staging System that utilizes β2m and serum albumin be changed to include metaphase cytogenetic and FISH analyses? No Robert Z. Orlowski, MD, PhD Yes Rafael Fonseca, MD 10:05 am Coffee break CML 10:25 am Debate: Should younger patients who fail to achieve CCyR after 12 months of imatinib be referred for allogeneic-sct or be given second generation TKIs? Allogeneic-SCT Speaker invited Second generation TKIs Michael J. Mauro, MD 10:55 am Debate: What should be the frontline therapy for high risk newly diagnosed CML patients? Imatinib (standard dose) Michael J. Mauro, MD Other options (high-dose imatinib, 2nd generation TKI, combinations) Jorge Cortes, MD 11:25 am Debate: What is significantly more clinically important - Complete Molecular Remission or Complete Cytogenetic Response? Complete Molecular Remission Speaker invited Complete Cytogenetic Response Jorge Cortes, MD 11:55 am Lunch

9 Great Debates and Updates in April 17-18, 2009 I Boca Raton, Florida, USA scientific agenga continued MDS 1:00 pm Debate: For a symptomatic 67 year old man with intermediate-1 MDS with Hgb=9.2, ANC=1300, and Platelet count=115,000 plus cytogenetic changes of deletion 5q plus deletion 2-q, what would be the most appropriate therapy hypomethylating agents or immunomodulatory compounds? Hypomethylating compounds David P. Steensma, MD Immunomodulatory compounds Gail Roboz, MD 1:30 pm Debate: Management of low risk MDS Best Supportive Care versus hypomethylating agents BSC Gail Roboz, MD Hypomethylating agents David P. Steensma, MD 2:00 pm Emerging Therapies for MDS Stephen Nimer, MD 2:25 pm Coffee break CLL 2:45 pm Debate: Should molecular biomarkers or clinical prognostic factors be used to decide therapy for CLL patients? Molecular biomarkers Matt Kalaycio, MD Clinical prognostic factors Michael J. Keating, MB, BS 3:15 pm Debate: What is the most appropriate therapy for CLL patients who relapse >12 months following induction therapy with a fludarabine-rituximab based regimen? 3 :45 pm Adjourn Alemtuzumab Matt Kalaycio, MD Purine analog-based therapy Michael J. Keating, MB, BS Bendamustine-based therapy Ann F. Mohrbacher, MD *Please visit for the most up-to-date agenda and to register

10 Registration Fees Regular $ Nurses/Residents/Students* $75.00 *proof of eligibility must accompany registration Registration Procedures To Register: You may register online by April 9, 2009 at by calling Imedex at +1 (678) or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified. Payment: To pre-register, registration and payment must be received no later than April 9, Please register onsite after this date. Contact Imedex at +1 (678) or visit our website at to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received. Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program. Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@ imedex.com no later than April 9, The amount of registration fees remitted, minus a $25 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after April 9, The Registration and Information Desk will be staffed: Friday, April 17, :00 am 5:00 pm Saturday, April 18, :00 am 4:00 pm 4 EASY WAYS TO REGISTER: Online... FAX US... You can fax your registration 24 hours a day. +1 (678) CALL US... The Registrar will take your registration over the phone. +1 (678) MAIL US... Imedex 4325 Alexander Drive Alpharetta, GA , USA Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.